EGFR and non-small cell lung carcinoma: There are no completed targeted therapy clinical trials and no current neoadjuvant standard of care in the management of EGFR mutation-positive (EGFRm) NSCLC, but several studies (NCT01833572, NCT01217619, EMERGING-CTONG 1103, NEOS, and NCT03433469) are now recruiting (12–14).